期刊文献+

吉非替尼致间质性肺炎1例 被引量:15

Interstitial pneumonia caused by gefitinib in one patient
下载PDF
导出
摘要 吉非替尼(gefitinib)自2003年开始用于治疗晚期非小细胞肺癌以来,已成为肺癌靶向治疗的一种重要药物。国内,中华医学会和中国抗癌协会制定的肺癌诊疗指南中,吉非替尼也被列为ⅢB、Ⅳ期非小细胞肺癌二线治疗的可选药物。但间质性肺炎是吉非替尼罕见且可以致命的不良反应,现报道1例肺癌病人口服吉非替尼后致间质性肺炎病例。
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2007年第11期878-879,共2页 Chinese Journal of New Drugs and Clinical Remedies
关键词 吉非替尼 肺肿瘤 肺疾病 间质性 药物不良反应 gefitinib lung neoplasms lung diseases, interstitial adverse drug reactions
  • 相关文献

参考文献6

  • 1LYNCH TJ, BELL DW, SORDELLA R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350(21): 2129-2139.
  • 2陈玲,陈强,叶韵斌.吉非替尼敏感性预测指标的研究现状[J].中国新药与临床杂志,2006,25(11):864-868. 被引量:9
  • 3吴一龙,廖美琳,蒋国梁,等.临床诊疗指南-肿瘤学分册[M].北京:人民卫生出版社,2005:96-135.
  • 4KRIS MG. How today, s developments in the treatment of non-small cell lung cancer will change tomorrow, s standards of care [J]. Oncologist, 2005, 10 Suppl 2:23-29.
  • 5张晓彤,李龙芸,王树兰,穆新林,王孟昭.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180-183. 被引量:31
  • 6OKAMOTO I, FUJII K, MATSUMOTO M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with nonsmall cell lung cancer[J]. Lung Cancer, 2003, 40(3): 339-442.

二级参考文献37

  • 1Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase Ⅲ trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol, 2001, 19: 1734-1742.
  • 2Schiller JH, Harrington D, Belani CP, et al. For the Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 2002, 346: 92-98.
  • 3Mill AB, Hoogstrsten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47: 207-214.
  • 4Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9: 129-137.
  • 5Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79: 538-544.
  • 6Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Reserarsh Award Lecture. Clin Cancer Res, 2000, 6: 747-753.
  • 7Ciardiello F, Caputo R, Pomatico C, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res, 2001, 7: 1459-1465.
  • 8Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21: 2237-2246.
  • 9LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res, 2003, 9:2040-1048.
  • 10Kris M, Natale R, Herbst R, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290:2149-2158.

共引文献37

同被引文献214

引证文献15

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部